Filing Details

Accession Number:
0001061983-17-000065
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-11-06 20:19:01
Reporting Period:
2017-11-02
Accepted Time:
2017-11-06 20:19:01
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1061983 Cytokinetics Inc CYTK Pharmaceutical Preparations (2834) 943291317
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1674232 Gordon Caryn Mcdowell 280 East Grand Avenue
South San Francisco CA 94080
Gc & Chief Compliance Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2017-11-02 77 $6.67 17,982 No 4 M Direct
Common Stock Disposition 2017-11-02 2,460 $12.90 15,522 No 4 S Direct
Common Stock Acquisiton 2017-11-02 653 $6.67 16,175 No 4 M Direct
Common Stock Disposition 2017-11-02 1,800 $13.00 14,375 No 4 S Direct
Common Stock Acquisiton 2017-11-02 625 $6.37 15,000 No 4 M Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 M Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Incentive Stock Option (right to buy) Disposition 2017-11-02 625 $0.00 625 $6.37
Common Stock Incentive Stock Option (right to buy) Disposition 2017-11-02 653 $0.00 653 $6.67
Common Stock Non-Qualified Stock Option (right to buy) Disposition 2017-11-02 77 $0.00 77 $6.67
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
11,875 2016-05-29 2025-05-29 No 4 M Direct
19,343 2016-03-23 2026-02-23 No 4 M Direct
1,075 2016-03-23 2026-02-23 No 4 M Direct
Footnotes
  1. The exercise reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2017.
  2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2017.